Applied BioCode Corp

Applied BioCode Corp maintains a strong liquidity position, with cash and equivalents amounting to 489.24 million TWD, representing 50.8% of total assets. The company's liquidity FPT score indicates a robust ability to meet short-term obligations, supported by a current ratio of 6.99. However, negative operating and free cash flows of -58.18 million TWD and -50.47 million TWD, respectively, suggest ongoing operational challenges. Profitability metrics reveal significant underperformance relative to industry norms. The company reported a net loss of 63.12 million TWD, with a return on equity of -10.21% and a return on assets of -6.56%. These figures fall well below the typical thresholds for biotechnology firms, indicating a need for strategic cost management or revenue diversification. Geographically, Applied BioCode Corp's revenue concentration remains undisclosed in the latest filings, but the absence of segment-specific data suggests a lack of transparency in its geographic and product diversification. This opacity could pose risks in volatile markets or during regulatory shifts. Growth prospects appear constrained, with the company reporting a net loss in the most recent fiscal year. Analyst estimates for revenue and EPS remain negative, with last actual EPS at -1.96 TWD and revenue at 475.20 million TWD. These figures indicate a lack of momentum in scaling operations or improving profitability. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.05 suggests minimal leverage, but the absence of positive cash flows could pressure liquidity in the medium term. No dilution sources were identified in recent filings, and the dilution potential remains low. Recent events include the publication of the latest financial results, which highlight continued operational losses and negative cash flows. No material regulatory or litigation events were disclosed in the most recent filings, but the company's performance remains a concern for stakeholders.